J. Adams

发表

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

L. Dick, R. Stein, M. Behnke, 1998, Bioorganic & medicinal chemistry letters.

The proteasome inhibitor PS-341 in cancer therapy.

R. Herbst, B. Teicher, J. Adams, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides.

S. J. Campbell, R. Snow, R. Barton, 1996, Journal of medicinal chemistry.

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis.

P. Elliott, J. Davis, J. Davis, 1998, Proceedings of the National Academy of Sciences of the United States of America.

The prognostic influence of bcl-2 in malignant glioma

A. Gregor, J. Ironside, H. Potts, 2002, British Journal of Cancer.

Proteasome inhibition measurements: clinical application.

P. Elliott, E. Lightcap, V. Chau, 2000, Clinical chemistry.

Crystal structure of nevirapine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, and computational alignment with a structurally diverse inhibitor.

P. Mui, K. D. Hargrave, J. Adams, 1992, Journal of medicinal chemistry.

The ρ-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34+ CML progenitor cells

J. Burthem, A. Whetton, E. Spooncer, 2007, Leukemia.

Recent advances in understanding proteasome function.

J. Adams, P. Elliot, 1999, Current opinion in drug discovery & development.

Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase.

S. Rogers, C. Pargellis, R. Ingraham, 1991, The Journal of biological chemistry.

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

P. Elliott, P. Richardson, D. Chauhan, 2001, Cancer research.

Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial

G. Demetri, S. George, J. Morgan, 2007 .

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

L. Dick, R. Stein, M. Behnke, 1998, Bioorganic & medicinal chemistry letters.

Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.

J. Adams, K. Grozinger, J. Wu, 1990, Science.

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

E. Sausville, P. Elliott, J. Johnson, 1999, Cancer research.

Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.

J. Proudfoot, P. Grob, U. Patel, 1995, Journal of medicinal chemistry.

A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site.

J. Proudfoot, P. Grob, J. Wu, 1991, Biochemistry.

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587.

J L Sullivan, R. Koup, K. Grozinger, 1991, The Journal of infectious diseases.

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

Z Chen, E. Sausville, P. Elliott, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

P. Elliott, J. Tepper, J. Cusack, 2001, International journal of radiation oncology, biology, physics.

New insights into proteasome function: from archaebacteria to drug development.

A. Goldberg, R. Stein, J. Adams, 1995, Chemistry & biology.

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

P. Elliott, J. Cusack, A. Baldwin, 2001, Cancer research.

Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

P. Elliott, R. Kerbel, S. Man, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome.

P. Elliott, E. Conner, V. Palombella, 1999, Methods in enzymology.

Selective Inhibition of Casein Kinase 1 Epsilon Minimally Alters Circadian Clock Period

A. Loudon, E. Maywood, K. Walton, 2009 .

Proteasome inhibition in cancer: development of PS-341.

J. Adams, Julian Adams, 2001, Seminars in oncology.

Proteasome inhibition: A novel mechanism to combat asthma.

P. Elliott, J. Adams, J. Adams, 1999, The Journal of allergy and clinical immunology.

Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.

C. Cywin, P. Grob, K. Barringer, 1998, Journal of medicinal chemistry.

Differences in phorbol-ester-induced down-regulation of protein kinase C between cell lines.

W. Gullick, J. Adams, 1989, The Biochemical journal.

Volume regulation of natural killer cells under hypotonic stress: comparison with T and B cell subpopulations.

H. Dosch, J. Rusthoven, J. Adams, 1986, Immunology letters.

570 POSTER Overcoming resistance to tyrosine kinase inhibitors (TKls) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 inhibitor

J. Fletcher, G. Demetri, S. George, 2006 .

Inhibition of herpes simplex virus type 1 ribonucleotide reductase by substituted tetrapeptide derivatives.

J. DiMaio, N. Moss, P. Beaulieu, 1993, Journal of medicinal chemistry.